CRISPR Therapeutics AG
CRSP
$48.41
-$2.04-4.04%
NASDAQ
| 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | |
|---|---|---|---|---|---|
| Revenue | 68.55% | -97.58% | 47.67% | 72.53% | 71.63% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 68.55% | -97.58% | 47.67% | 72.53% | 71.63% |
| Cost of Revenue | -11.90% | 67.04% | 24.33% | -13.04% | 5.57% |
| Gross Profit | 12.44% | -193.49% | -24.18% | 13.37% | -5.30% |
| SG&A Expenses | -10.95% | 1.52% | -2.80% | -2.90% | 7.48% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | -11.78% | 55.20% | 20.06% | -11.74% | 5.81% |
| Operating Income | 12.25% | -139.62% | -19.91% | 12.02% | -5.57% |
| Income Before Tax | 9.49% | -255.08% | -24.40% | -65.65% | -16.42% |
| Income Tax Expenses | -24.35% | -12.29% | -29.34% | 0.39% | 53.18% |
| Earnings from Continuing Operations | 9.61% | -250.07% | -23.85% | -64.98% | -16.64% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 9.61% | -250.07% | -23.85% | -64.98% | -16.64% |
| EBIT | 12.25% | -139.62% | -19.91% | 12.02% | -5.57% |
| EBITDA | 12.36% | -149.56% | -21.10% | 12.29% | -5.84% |
| EPS Basic | 19.13% | -214.02% | -15.62% | -60.91% | -11.02% |
| Normalized Basic EPS | 19.02% | -218.57% | -16.13% | 13.48% | -10.81% |
| EPS Diluted | 19.12% | -214.04% | -15.84% | -61.07% | -10.66% |
| Normalized Diluted EPS | 19.02% | -218.57% | -16.13% | 13.48% | -10.81% |
| Average Basic Shares Outstanding | 11.77% | 11.47% | 7.12% | 2.53% | 5.07% |
| Average Diluted Shares Outstanding | 11.77% | 11.47% | 7.12% | 2.53% | 5.07% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |